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Abstract
Oral treatment with the dual-receptor tyrosine kinase
inhibitor AEE788 effectively reduces the number of
peritumoral lymphatic vessels and the incidence of
lymph node metastasis in nude mice with human HT29
colon cancer cells growing in the cecum. Whether
inhibition of lymphnodemetastasis in colon cancer can
be achieved by directly targeting lymphatic endothelial
cells remains unclear. Using a microsurgical approach,
we generated conditionally immortalized lymphatic
endothelial cell lines from the H-2Kb-tsA58mouse mes-
entery and characterized these cells for the expression
of lymphatic endothelial cell markers. Lymphatic endo-
thelial cells were stimulated in culture with an array of
tumor cell–produced cytokines, leading to the identi-
fication of redundant pathways for proliferation and
survival. Treatment with AEE788 decreased the migra-
tion, proliferation, and survival of lymphatic endothelial
cells, demonstrating that oral treatment with AEE788
effectively decreases the incidence of colon cancer
lymphatic metastasis due, in part, to the direct inhibi-
tion of lymphatic endothelial cell signaling.
Neoplasia (2006) 8, 747–757
Keywords: Lymphatic endothelial cells, lymph nodemetastasis, colon cancer,
tyrosine kinase, lymphangiogenesis.
Introduction
Colon cancer frequently metastasizes to regional lymph
nodes, affecting prognosis and disease outcome [1]. In
several tumor models, the formation of new lymphatic ves-
sels from pre-existing lymphatics (i.e., lymphangiogenesis) is
associatedwith anenhanced spreadof tumor cells to regional
lymph nodes [2–6]. A rapidly expanding array of growth
factors has been shown to regulate lymphangiogenesis,
including the vascular permeability factor/vascular endo-
thelial growth factor (VPF/VEGF) family of proteins, which
includes VEGF-A, VEGF-C, VEGF-D, and platelet-derived
growth factor (PDGF). In addition, basic fibroblast growth
factor (bFGF), hepatocyte growth factor (HGF), insulin-like
growth factor (IGF)-1/2, and epidermal growth factor (EGF)
also mediate lymphatic endothelial cell biology [7,8]. Im-
provements in the ability to identify lymphatic vessels have
allowed more extensive studies examining the potential role
of lymphatic vessels during metastasis [9]; however, the ma-
jority of these studies have been confined to the dermis. Thus,
the role of lymphangiogenesis in colon cancer metastasis re-
mains unclear.
Results of histologic studies of human colon cancer have
suggested that pathologic conditions, including cancer, are as-
sociatedwith alterations in both the density and the distribution of
lymphatic vessels [10–12]. Tumor cell invasion of lymphatic
vessels has been shown to be an independent prognostic factor
in colon cancer [13], and an increased density of lymphatic
vessels within clinical specimens of colon cancer has been
shown to be predictive of lymph node metastases, suggesting
that lymphangiogenesis is essential for the spread of colon
cancer to regional and distant lymph nodes [14–16]. Another
potential link between tumor-mediated lymphangiogenesis and
lymph node metastasis in colon cancer is suggested by the
finding that nodal metastasis correlates with the expression of
lymphangiogenic growth factors by tumor cells [17–20].
Antivascular therapy can lead to the destruction of neo-
plasms [21], and systemic administration of receptor tyrosine
kinase inhibitors can produce antitumor effects by inhibiting
receptor phosphorylation in tumors and tumor-associated en-
dothelial cells [22–27]. Whether treatment of colon cancer
and inhibition of lymph node metastasis can be achieved by di-
rectly targeting the lymphatic vasculature are unknown.
We have previously reported that oral administration of
AEE788, a dual-receptor tyrosine kinase inhibitor of the epi-
dermal growth factor receptor (EGFR) and the vascular epi-
dermal growth factor receptor-2 (VEGFR-2)/kinase domain
receptor [28], can decrease the incidence of lymphatic metas-
Abbreviations: EOMA, murine hemangioendothelioma; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenol-tetrazolium bromide
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tasis in nude mice with orthotopic HT29 human colon carci-
noma growing in the cecum [22]. However, it remained
unclear whether the decrease in lymphatic metastasis was
mediated by the actions of AEE788 on the tumor-associated
lymphatic vasculature. In the present study, we compared
peritumoral lymphatic vessel density (LVD) in control and in
AEE788-treated HT29 human colon cancers growing in the
cecum of nude mice to assess the potential effects of
AEE788 on lymphatic endothelial cells. We developed a
novel approach to isolate conditionally immortalized lym-
phatic endothelial cells from the mouse mesentery and
examined the direct consequences of AEE788 exposure
on lymphatic endothelial cell signaling, survival, proliferation,
and migration.
Materials and Methods
Cell Lines and Culture Conditions
HT29 human colon cancer cells were maintained in min-
imum essential medium (MEM) supplemented with 10% fetal
bovine serum (FBS), sodium pyruvate, nonessential amino
acids, L-glutamine, a two-fold vitamin solution (Life Technol-
ogies, Grand Island, NY), and a penicillin/streptomycin mix-
ture (Flow Laboratories, Rockville, MD). Cultures were
maintained at 37jC in 5% CO2 and 95% air. Murine heman-
gioendothelioma (EOMA) and NIH-3T3 fibroblasts were
maintained as described for HT29 tumor cells. Cultures were
free ofMycoplasma and pathogenic murine viruses (assayed
by Science Applications International Co., Frederick, MD).
Brain microvascular cells were isolated as previously de-
scribed [29]. Lymphatic endothelial cell lines and brain mi-
crovascular endothelial cells were maintained at 33jC in 5%
CO2 and 95% air in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented as described above.
Reagents
AEE788 (Novartis Pharma, Basel, Switzerland) is an
adenosine triphosphate–competitive low-molecular-weight
tyrosine kinase family inhibitor of EGFR and VEGFR-2 [28].
AEE788was diluted in dimethyl sulfoxide (DMSO) before oral
dosing. The following primary antibodies were used: LYVE-1
and podoplanin (Research Diagnostics, Flanders, NJ);
mouse CD31 and VEGFR-3 (PharMingen, San Diego, CA);
Prox-1 (AngioBio, Del Mar, CA); VEGFR-2 (SC504) and
VEGFR-3 (SC637) (Santa Cruz Biotechnology, Santa Cruz,
CA); EGFR (Zymed, San Francisco, CA); phospho-EGFR
(Biosource International, Inc., Carlsbad, CA); phospho-
VEGFR-2/3 (Oncogene,Boston,MA); streptavidin-conjugated
Alexa fluorescent 594, anti-rat Alexa fluorescent 594, and
anti-rabbit Alexa 488 (Molecular Probes, Eugene, OR);
phospho-Akt (Ser-473), Akt, phospho-ERK1/2 (Thr-202/Tyr-
204), and P44/42 MAPK (Cell Signaling Technology, Bever-
ley, MA); SV40 large T antigen (Oncogene Research, San
Diego, CA); smooth muscle actin and b-actin (Sigma-Aldrich,
St. Louis, MO); and vinculin (Serotec, Raleigh, NC). Sec-
ondary reagents included peroxidase-conjugated F(abV)2
fragments from Jackson ImmunoResearch (West Grove,
PA). Anti-rabbit and anti-mouse conjugated horseradish per-
oxidase antibodies were purchased from Bio-Rad Laborato-
ries (Hercules, CA). A tyramide signal amplification reagent
(NEN Life Science Products, Boston, MA) was also used in
the study according to the manufacturer’s instructions.
Animals
Male athymic nude mice (NCI-nu) were purchased from
theNational Cancer Institute Frederick Cancer Research and
Development Center (Frederick, MD). Mice homozygous for
a temperature-sensitive SV40 large T antigen (H-2Kb-tsA58
mice; CBA/caC57BL/10 hybrid) were purchased from
Charles River Laboratories (Wilmington, MA). Themice were
housed under specific pathogen-free conditions in accor-
dance with institutional guidelines and the current regula-
tions of the National Institutes of Health, the US Department
of Health and Human Services, and the US Department
of Agriculture.
Orthotopic Implantation of Tumor Cells
To produce orthotopic cecal tumors, HT29 cells were
harvested from subconfluent cultures by brief exposure to
0.25% trypsin and 0.02% ethylenediaminetetraacetic acid
(EDTA). Cells were washed once in serum-free medium
and resuspended in Hank’s balanced salt solution (HBSS).
Only single-cell suspensions with more than 90% viability
were used for injection. Cells (1106) in 50 ml of HBSS were
injected orthotopically into the cecal wall of nude mice as
described previously [22].
Treatment of Established Human Colon Carcinoma Tumors
Growing in the Cecum of Athymic Nude Mice
Treatment was performed as previously described [22].
Briefly, 2 weeks after cecal injection, 10 mice were each
randomly assigned to receive one of the following treatments:
1) oral gavage of DMSO/0.5% Tween 80 diluted 1:20 with
water, thrice a week, and intraperitoneal injection of phos-
phate-buffered saline (PBS), once a week (control group);
or 2) oral gavage of AEE788 (50 mg/kg), thrice a week, and
intraperitoneal injection of PBS, once a week.
Necropsy Procedures and Histologic Studies
Mice were euthanized with pentobarbital sodium (Abbot
Laboratories, North Chicago, IL) on Day 36 of treatment, and
tumors growing within the cecum were excised. Tumor tissue
was embedded in an ornithine carbamyl transferase com-
pound (Miles Laboratories, Elkhart, IN), frozen in liquid ni-
trogen, and stored at 70jC. All macroscopically enlarged
mesenteric lymph nodes were harvested and then examined
histologically for the presence of metastases.
Determination of LVD
Frozen sections were fixed by sequential immersions in
ice-cold acetone, acetone–chloroform (50:50 vol/vol), and
acetone solution (5 minutes each). Slides were rinsed with
PBS and blockedwith amixture of PBS containing 5%normal
horse serum and 1% normal goat serum for 30 minutes at
room temperature. Tissue samples were then incubated
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overnight at 4jC with anti-mouse LYVE-1 antibody, washed,
and incubated for 1 hour with anti-rabbit Alexa 488. Samples
were then washed and incubated overnight at 4jCwith either
anti-CD31 antibody or anti–VEGFR-3 antibody, washed, and
incubated at room temperature for 1 hour with the appropriate
Alexa 594 antibody. Cell nuclei were stained using Hoechst
33342 (Polysciences, Inc., Warrington, PA), and the slides
were mounted with a glycerol/PBS medium containing 0.1 M
propyl gallate (Sigma-Aldrich) to minimize fluorescent
bleaching. LVD was evaluated by two independent investi-
gators using a modification of the method previously de-
scribed [30] for determining the blood microvascular density
of tumors. Briefly, regions of the tumor that stained intensely
for LYVE-1 were selected by low-power (original magnifica-
tion, 40 magnification) scanning of the section. The mean
LVD of these ‘‘hot spots’’ was then quantified by counting the
number of lymphatic vessels at higher (original magnification,
100) magnification in a minimum of three microscopic
fields for each tumor sample. Immunofluorescence micros-
copy was performed using a Zeiss Axioplan fluorescence
microscope (Carl Zeiss, Inc., Thornwood, NY) equipped with
a 100-W Hg lamp and narrow bandpass excitation filters.
Representative imageswere obtained using a cooled charge-
coupled device Hamamatsu C5810 camera (Hamamatsu
Photonics, Bridgewater, NJ) and Optimas software (Media
Cybernetics, Silver Spring, MD). Composite figures were
made using PhotoShop software (Adobe Systems Incorpo-
rated, Mountain View, CA).
Expression of VEGFR-2, VEGFR-3, and EGFR
in Tumor-Associated Lymphatic Vessels
HT29 tumors were stained for the lymphatic endothelial
cell marker LYVE-1, as described above. The slides were
then blocked in rabbit serum diluted in fish gel (20 mg/ml) for
30minutes at room temperature and thenwith goat anti-rabbit
F(abV)2 fragments diluted in fish gel. The slides were incu-
bated with antibodies directed against either EGFR, VEGFR-
2, VEGFR-3, or their respective phosphorylated forms for
24 hours at 4jC. The slides were rinsed thrice with PBS and
then incubated with anti-rabbit Alexa 594 secondary antibody
(1:500; Molecular Probes) for 45 minutes. The slides were
rinsed and then analyzed by fluorescence microscopy.
Microsurgical Isolation of Lymphatic Endothelial Cells
H-2Kb-tsA58 mice were anesthetized with an intra-
peritoneal injection of pentobarbital sodium. The hair was
clipped, and the skin was prepared for surgery in standard
fashion. A ventral midline incision was made, allowing exte-
riorization of the cecum and associated mesentery. Isosulfan
blue (100 ml; Ben Venue Laboratories, Inc., Bedford, OH) was
injected into the cecal wall, allowing rapid visualization of the
draining mesenteric lymph node and the primary collecting
duct. A curved stainless-steel cutting needle and micro-
forceps were used to dissect lymphatic vessels from the node
and the surrounding mesentery; at this time, the mice were
killed by cervical dislocation. Lymphatic vessels were placed
into individual wells of a six-well plate (previously coated
with 1% gelatin) containing DMEM supplemented with 10%
FBS. Primary cultures were supported at 33jC in amixture of
5% carbon dioxide and 95% oxygen; the medium was
replaced as needed.
Derivation of Clonal Populations of Mesenteric Lymphatic
Endothelial Cells
Cells were harvested from subconfluent cultures by over-
laying the monolayer with a solution of 0.25% trypsin and
0.1% EDTA. Cells were resuspended in DMEM containing
10% FBS, and the number of detached cells was adjusted to
achieve a final concentration of 5 cells/ml. Cell suspension
(100 ml) was then placed into individual wells of 96-well
plates. Cells were allowed to incubate overnight at 33jC
and were then examined under phase-contrast microscopy
to identify wells containing only one cell. Wells with only one
cell were marked, the plates were returned to the incubator,
and the medium was changed as necessary. Four clonal
populations were randomly selected and combined for ex-
pansion and subsequent comparison with a pooled popula-
tion of cells.
Immunohistochemical Evaluation of Immortalized
Mesenteric Lymphatic Endothelial Cells
Cells were seeded onto two-chamber slides at a density of
2.5  104 cells/well in DMEM containing 10% FBS and
incubated at 37jC for 72 hours. Tissue fixation was carried
out by immersion in ice-cold acetone for 15 minutes, and the
slides were blocked in PBS containing 5% normal horse
serum and 1%normal goat serum. The slides were incubated
overnight at 4jC with primary antibodies directed against
LYVE-1, podoplanin, Prox-1, or VEGFR-3. The slides were
rinsed thrice with PBS and then incubated with the appropri-
ate peroxidase-conjugated secondary antibody for 1 hour at
room temperature. The slides were washed and then incu-
bated in a biotin tyramide solution for 10 minutes, and then
incubated for 1 hour with streptavidin-conjugated Alexa
fluorescent 594. Cell nuclei were labeled with Hoechst
33342. Fluorescent bleaching was minimized by mounting
the slides with a glycerol/PBS medium containing 0.1 M
propyl gallate. Immunofluorescence microscopy was per-
formed using a Zeiss Axioplan fluorescence microscope, as
described above. Composite photographs were made using
PhotoShop software (Adobe Systems Incorporated).
Western Blot Analysis
To determine the kinetics of the expression of the temper-
ature-sensitive SV40 large T antigen, 4  105 lymphatic
endothelial cells were plated onto a series of 10-cm culture
dishes in DMEM containing 10% FBS and placed in either an
incubator set at 33jC for 72 hours or an incubator set at 37jC
for 24, 48, or 72 hours. At each time point, cells were washed
twice with PBS and then lysed with buffer [20 mM Tris–HCl
(pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 2 mM sodium orthovanadate,
20 mM leupeptin, and 0.15 U/ml aprotinin]. Protein concen-
trations were determined using the Bradford method (Bio-
Rad Laboratories), and 50 mg of total protein resolved in 8%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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under reducing conditions was transferred to polyvinylidene
difluoride membranes. Membranes were blocked with 5%
(weight/volume) nonfat dried milk in Tris-buffered saline
(pH 7.5; 100 mM NaCl, 50 mM Tris, and 0.1% Tween 20)
(Sigma-Aldrich) for 1 hour and then incubated overnight at
4jCwithanantibodydirectedagainst theSV40 largeTantigen.
Immunodetection was performed using the corresponding
secondary horseradish peroxidase–conjugated antibody,
andactivity was detected using enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ).
Akt and ERK1/2 Signaling in Mesenteric Lymphatic
Endothelial Cells
In this series of experiments, we sought to identify factors
that could activate Akt and ERK1/2 in mesentery-derived
lymphatic endothelial cells. Lymphatic endothelial cells
were seeded onto several 10-cm dishes at a density of 4 
105 cells/dish in DMEM containing 10% FBS and placed at
37jC for 54 hours, at which time the incubation medium was
aspirated and replaced with serum-free DMEM. After serum
starvation for 18 hours at 37jC, the incubation medium was
aspirated and replaced with either fresh serum-free DMEM
or serum-free DMEM supplemented with 100 ng/ml VEGF-C
or VEGF-D (R&D Systems, Minneapolis, MN) for 5, 15, 30, or
45 minutes. In parallel studies, additional plates were stimu-
lated with 20 ng/ml VEGF-A (R&D Systems), PDGF-BB,
bFGF, or EGF (Invitrogen, Carlsbad, CA). At the correct time
point, cells were washed twice with ice-cold PBS and lysed
with buffer, and the extent of Akt and ERK1/2 activation was
determined using Western blot analysis.
AEE788 Inhibition of Akt and ERK1/2 Phosphorylation
in Mesenteric Lymphatic Endothelial Cells
Lymphatic endothelial cells were seeded onto several six-
well plates at a density of 1  105 cells/well in DMEM
containing 10% FBS and placed at 37jC for 54 hours. The
incubation medium was aspirated and replaced with serum-
free DMEM. After serum starvation for 18 hours at 37jC,
lymphatic endothelial cells were treated for with AEE788 (0,
0.25, 0.5, 1.0, 2.5, or 5.0 mM) for 120 minutes, followed by an
additional 15-minute incubation in the presence or absence of
growth factors. Cells were washed twice with ice-cold PBS
and lysed with buffer, and protein expression was determined
by Western blot analysis as described above.
Cytotoxicity and Proliferation Assays
Lymphatic endothelial cells were incubated at 37jC for
72 hours, plated in 96-well plates (5  103 cells per well)
containing 100 ml of DMEM plus 10% FBS, and then incu-
bated at 37jC for an additional 24 hours. The medium was
aspirated and replaced with 200 ml of serum-free MEM with
or without specified concentrations of AEE788, or MEM
containing 5% FBS with or without AEE788. After 72 hours,
the number of cells that were metabolically active was
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol-
tetrazolium bromide (MTT) assay [31]. Briefly, 0.42 mg/ml
MTT was added to the cultures. After 2 hours, the cells were
lysed with 60 ml of DMSO. MTT conversion to formazan by
metabolically active cells was measured with an MR-5000
96-well microtiter plate reader at 570 nm (Dynatech, Inc.,
Chantilly, VA). Assays were performed for a minimum of
three times.
The effect of AEE788 on cell viability was also evaluated
using propidium iodide staining. For these experiments,
lymphatic endothelial cells were plated in a series of
100-mm dishes at a density of 1  106 cells/dish. After a
24-hour incubation period, the medium was replaced with
MEM containing 5% FBS or the same medium with either
0.5 or 5.0 mM AEE788. Additional plates were treated in the
same fashion, except that FBS was not included in the
medium. After a 48-hour incubation period, the cells were
fixed with ice-cold 70% ethanol and placed at 20jC for
24 hours. Cells were pelleted (400 g for 5 minutes) in tubes
and washed once in staining buffer (PBS with 2% fetal calf
serum and 0.01% NaN3). Cells were treated with 15 mg/ml
ribonuclease A (Sigma-Aldrich) for 30 minutes at 37jC. Cells
were stained with 50 mg/ml propidium iodide in staining buffer
for 30 minutes at room temperature. Samples were placed
on ice and then analyzed by flow cytometry.
Migration Assays
Lymphatic endothelial cells were incubated at 37jC for
72 hours, trypsinized, and washed in MEM containing 5%
FBS. Cells were washed again and resuspended in serum-
free MEM. Cells (2.0  104) in 200 ml were plated on top of
24-well polycarbonate transwell migration inserts (3.0 mm
pore size; Fisher Scientific, St. Louis, MO), which had been
placed onto 24-well plates containing 500 ml of serum-free
MEM or MEM containing 10% FBS. Additional wells con-
tainedAEE788 at concentrations of 0.5 or 5.0 mM inMEMplus
10% FBS. Plates were incubated at 37jC for 20 hours, at
which time the cells from the upper compartment were
manually removed with cotton swabs and the membrane
was fixed and processed for cell counting. Cells that migrated
to the underside of the membrane were counted under
40 magnification. All assays were performed in triplicate.
Statistical Analysis
Statistical analyses were performed using GraphPad
Prism software (San Diego, CA). P values were calculated
using one-way analysis of variance. Means determined to be
significantly different (P < .05) were then subjected to post
hoc analysis using Tukey’s multiple comparison testing.
Results
Immunofluorescent Staining of HT29 Tumors
To determine the specificity of the lymphatic vessel stain-
ing of HT29 tumors, we performed a dual staining of tissue
samples with LYVE-1 and CD31 antibodies. CD31+ vascular
structures were found within and adjacent to HT29 tumors.
LYVE-1+ cells were absent from HT29 tumors (Figure 1A).
The peritumoral staining of irregularly shaped thin-walled
vessels (consistent with lymphatic vessels) for LYVE-1 was
evident and colocalized with some, but not all, CD31+ vessels
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(Figure 1A). VEGFR-3 was also found to colocalize with posi-
tively stained LYVE-1 vessels (data not shown).
Determination of LVD
To determine the effects of AEE788 therapy on LVD, HT29
tumors growing in the cecum of nude mice were stained
for the lymphatic-specific marker LYVE-1. For each tumor,
intensely staining peritumoral regionswere identified, and the
number of LYVE-1+ vessels within these regionswas counted
under 100 magnification. Treatment with AEE788 signifi-
cantly decreased peritumoral LVD in colon cancer tumors
compared with control mice (P < .001) (Figure 1B).
Microsurgical Isolation of Lymphatic Endothelial Cells
Injection of isosulfan blue (100 ml) into the cecal wall
permitted the rapid visualization of the mesenteric lym-
phatic collecting duct and associated draining lymph nodes
(Figure 2, A and B). Under the guidance of a dissecting
microscope, the mesenteric vessels of mice were dissected
and removed using a sterile, curved, stainless-steel cutting
needle (5-0) and microforceps (Figure 2, C and D). The ves-
sels were placed into individual wells of six-well plates pre-
coated with 1% gelatin, covered with medium containing 10%
FBS, and placed in an incubator set at 33jC. After a 72-hour
incubation period, we observed the attachment of some of the
vessels (Figure 2E ) and the outgrowth of a homogenous
population of cells with cobblestone morphology (Figure 2F ).
Characterization of Mesenteric Lymphatic Endothelial Cells
The immunohistochemical analysis of clonally derived lym-
phatic endothelial cells revealed the expression of LYVE-1,
Prox-1, podoplanin, and VEGFR-3 (Figure 2, G–K). Mesen-
teric lymphatic endothelial cells also internalized acetylated
low-density lipoproteins and formed tube structures on Matri-
gel surfaces (data not shown).
To assess the kinetics of the expression of SV40 large
T antigen, several clonal subcultures were transferred to an
incubator set at 37jC. In cells growing at 37jC, the expres-
sion of SV40 large T antigen declined in a time-dependent
manner to near undetectable levels by the 72-hour time point
(Figure 3A). To exclude any potential effects of SV40 large
Tantigen on lymphatic endothelial cell phenotype, lymphatic
endothelial cells were incubated for at least 72 hours in an
incubator set at 37jC.
Expression Profiling of Mesenteric Lymphatic Endothelial
Cells by Western Blot Analysis
To determine whether lymphatic endothelial cells ex-
hibited a phenotype distinct from that of fibroblasts or vascu-
lar endothelial cells, we examined the expression level of
several proteins. Vascular endothelial cells isolated from the
brain of H-2Kb-tsA58 mice [29] were used as controls be-
cause the brain is an organ devoid of lymphatic vessels and
any endothelial cell derived from this tissue will be of blood
vascular origin. Consistent with immunohistochemical anal-
ysis, lymphatic endothelial cells expressed robust levels of
VEGFR-3 and podoplanin.Moreover, the level of VEGFR-3 in
lymphatic endothelial cells was higher than that observed
in brain-derived endothelial cells, and VEGFR-3 was not
detected in either NIH-3T3 fibroblasts or EOMA cell lines.
Podoplanin was not detected in endothelioma cells and was
expressed at a low level in NIH-3T3 fibroblasts. Lymphatic
Figure 1. Immunohistochemical analysis of HT29 human colon cancer growing orthotopically within nude mice. (A) Representative example of the colocalization of
LYVE-1 (green), CD31 (red), and Hoescht (blue). The peripheral margin of the HT29 tumor is outlined in white. LYVE-1 staining is absent within the tumor, yet an
abundance of CD31+ vessels is evident. (B) Representative photomicrographs of LYVE-1+ peritumoral lymphatic vessels surrounding HT29 control or AEE788-
treated tumors. (C) The mean peritumoral LVD of HT29 tumors in mice receiving oral treatment with control or AEE788 was determined as described in the Materials
and Methods section. Oral treatment with AEE788 significantly reduced the peritumoral LVD of human HT29 tumors growing within the cecum of nude mice.
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endothelial cells and brain endothelial cells expressed similar
levels of podoplanin (Figure 3B). As expected, clonally de-
rived lymphatic endothelial cells were essentially negative for
a-smooth muscle actin, ruling out contamination with fibro-
blasts or smooth muscle cells.
Effects of AEE788 on Lymphatic Endothelial Cell
Proliferation, Survival, and Migration
To determine whether AEE788 inhibits the proliferation
and survival of mesenteric lymphatic endothelial cells, MTT
assays were performed. Lymphatic endothelial cells were
plated in a medium with or without serum and were treated
with 0, 0.5, or 5.0 mM AEE788, as described in the Materials
and Methods section. In both the presence and the absence
of serum, AEE788 inhibited proliferation in a dose-dependent
manner (Figure 4A). Data derived from experiments using
flow cytometry and propidium iodide staining paralleled
MTT results in that the incubation of lymphatic endothe-
lial cells in concentrations of 0.5 and 5.0 mM AEE788 in
serum-containing medium for 48 hours increased cell death
by 21%and 30%, respectively (data not shown). Treatment of
lymphatic endothelial cells with 0.5 and 5.0 mM AEE788 in
the absence of serum for 48 hours increased cell death by
30% and 60%, respectively (data not shown). In addition to
affecting lymphatic endothelial cell survival, AEE788 sig-
nificantly (P < .001) reduced lymphatic endothelial cell migra-
tion (Figure 4B).
Akt and ERK1/2 Signaling in Mesenteric Lymphatic
Endothelial Cells
Previous studies have shown that stimulation of VEGFR-3
initiates the activation of Akt and ERK1/2 pathways in lym-
phatic endothelial cells [32]. To determine whether these
signaling pathways were intact in cultured mesenteric lym-
phatic endothelial cells, we stimulated lymphatic endothelial
cells with a broad panel of growth factors and found that
VEGF-C or VEGF-D ligands resulted in the phosphorylation
of Akt and ERK1/2 (Figure 5). Stimulation with PDGF-BB or
EGF also produced a robust activation of Akt and ERK1/2
(Figure 5). VEGF-A (VPF) promoted the activation of Akt
Figure 2. Isolation of lymphatic endothelial cells. (A and B) Isosulfan blue injected into the cecal wall allows direct visualization of the afferent mesenteric collecting
duct and mesenteric lymph nodes. The arrows indicate the afferent mesenteric collecting duct, the asterisk represents the cecal injection site, and the mesenteric
lymph node is labeled L. (C and D) A curved stainless-steel cutting needle and microforceps were used to remove the vessel from the associated mesentery. (E)
Attachment of a lymphatic vessel in culture yields an outgrowth of cells. (F) Confluent monolayer of clonal lymphatic endothelial cells exhibits cobblestone
morphology. Representative examples of immunohistochemical staining for lymphatic markers. (G) Control. (H) LYVE-1. (I) Prox-1. (J) Podoplanin. (K) VEGFR-3.
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and the transient activation of ERK1/2, whereas the actions of
bFGF were more directed toward the phosphorylation of
ERK1/2 than toward the activation of Akt (Figure 5).
Effects of AEE788 on Mesenteric Lymphatic Endothelial
Cell Survival and Proliferation Pathways
Treatment of lymphatic endothelial cells with AEE788
inhibited survival and proliferation pathways in response to
stimulation with EGF. AEE788 also produced various levels
of inhibition in response to other lymphangiogenic growth
factors, including VEGF-A, VEGF-C, VEGF-D, bFGF, and
PDGF-BB (Figure 6).
Expression of Total and Phosphorylated VEGFR-2,
VEGFR-3, and EGFR in Peritumoral Lymphatic Vessels
Next, we performed double-immunofluorescence staining
to evaluate the effects of AEE788 on receptor tyrosine ki-
nase expression and activation on peritumoral lymphatic
vessels. Treatment with AEE788 had no effect on the levels
Figure 3. Characterization of lymphatic endothelial cells. (A) The temperate
expression of SV40 large T antigen was examined by Western blot analysis,
as described in the text. Cells were incubated at 37jC for 0, 24, 48, or 72 hours
before lysis. By 48 hours, the expression of SV40 large T antigen had been
markedly reduced. -Actin is shown as an internal loading control. (B) Cell
proteins were obtained and examined by Western blot analysis, as described
in the text. Clonally derived lymphatic endothelial cells express high levels of
VEGFR-3 and podoplanin. In addition, lymphatic endothelial cells are
essentially negative for the expression of a-smooth muscle actin (a-sm actin).
Vinculin is shown as an internal loading control. LyEC, lymphatic endothelial
cells; BrEC, brain endothelial cells.
Figure 4. Inhibition of lymphatic endothelial cell proliferation and migration in
response to treatment with AEE788. Lymphatic endothelial cells were treated
as described in the text. (A) Proliferation of lymphatic endothelial cells as
measured by MTT assay. Absorbance of 5  103 cells, as plated at the start
of the assay, is represented with a horizontal line. (B) Migration of lymphatic
endothelial cells toward a serum-free medium, a medium containing 10%
FBS, or a medium containing 10% FBS with either 0.5 or 5.0 M AEE788.
Data are expressed as mean ± SD and were repeated at least thrice with
comparable results. *P V .001.
Figure 5. Effect of growth factors on the phosphorylation of Akt and ERK1/2.
Under serum-free conditions, there is low-level activation of Akt and ERK1/2.
Addition of PDGF-BB (20 ng/ml), bFGF (20 ng/ml), VEGF-D (100 ng/ml),
VEGF-C (100 ng/ml), VEGF-A (100 ng/ml), or EGF (20 ng/ml) produces
varying increases in the phosphorylation of Akt and ERK1/2 over a 45-minute
time course. Total Akt and total ERK1/2 are shown as loading controls. P-Akt,
phosphorylated Akt; T-Akt, total Akt; P-ERK1/2, phosphorylated ERK1/2; T-
ERK1/2, total ERK1/2.
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of EGFR, VEGFR-2, or VEGFR-3 (Figure 7A); however,
AEE788 did inhibit the phosphorylation of these receptors
on peritumoral lymphatic vessels associated with HT29
human colon cancer (Figure 7B).
Discussion
We recently reported that oral treatment with AEE788 effec-
tively reduced the incidence of lymph node metastasis in
nude mice implanted with human HT29 colon cancer cells
into the cecum [22]. Because lymphangiogenesis has been
shown to enhance lymphatic metastasis in some tumor
models, we questioned whether AEE788 might have had a
direct effect on tumor lymphangiogenesis in orthotopically
implanted colon tumors. In this study, treatment with AEE788
significantly reduced the number of peritumoral lymphatic
vessels of HT29 tumors, establishing that AEE788 has a di-
rect effect on tumor lymphangiogenesis in this tumor model.
We used an anatomic dissection technique to isolate the
lymphatic endothelial cells of themousemesentery. Similar to
results generated from other laboratories [7,32,33], we noted
that a variety of growth factors stimulate the activation of
proliferation and survival programs in lymphatic endothelial
cells. In addition, we found that in vitro treatment of mesen-
teric lymphatic endothelial cells with AEE788 results in the
inhibition of lymphatic endothelial cell survival, proliferation,
and migration in response to multiple growth factors. Taken
together, these results demonstrate that oral administration
of AEE788 effectively decreases the incidence of lymphatic
metastasis and that this effect is due, in part, to the direct in-
hibition of lymphatic endothelial cell signaling.
The recent discovery of several lymphatic markers has
facilitated a more extensive study of lymphangiogenesis
and lymphatic metastasis [9]. For example, it is now known
that activation of VEGFR-3 by VEGF-C and VEGF-D signals
for survival and cell division in lymphatic endothelial cells
growing in cell culture [32,34–38]. VEGF-C and VEGF-D
have also been shown to induce lymphangiogenesis in vivo
[3,5,39] and to enhance lymphatic metastasis in some tumor
models [2–5]. Several other growth factors, including VEGF-
A, bFGF, PDGF-BB, HGF, IGF-1, IGF-2, and EGF, also pro-
mote lymphangiogenesis [7,8]. Indeed, the complexity of
lymphatic endothelial cell biology becomes more apparent
when the indirect effects of several known lymphangiogenic
growth factors are considered. For example, expression
levels of VEGF-C mRNA can be modulated by a variety of
proteins, including IGF-1R, PDGF, EGF, transforming growth
factor-b, tumor necrosis factor-a, and interleukin-1b [40–42].
VEGF-A has been shown to be chemotactic formacrophages
capable of producing an array of cytokines and growth
factors, including VEGF-C and VEGF-D [43,44]. For these
reasons, it is not surprising that VEGF-A can induce lym-
phangiogenesis through both direct [45] and indirect [43]
effects on the tumor microenvironment. Similar findings have
been reported for HGF [46,47] and bFGF [48]. EGF has been
shown to induce the proliferation of lymphatic endothelial
cells in culture and to upregulate the expression of lymphan-
giogenic growth factors [7,39,49,50].
Figure 6. AEE788 inhibits the phosphorylation of Akt and ERK1/2 within lymphatic endothelial cells. Stimulation of Akt and ERK1/2 is seen in response to treatment
with various growth factors. The blockade of Akt and ERK1/2 phosphorylation is most evident in cells treated with EGF, whereas intermediate blockade was
achieved in cells treated with VEGF-C, VEGF-D, or PDGF-BB. Only mild inhibition was evident in cells treated with VEGF-A or bFGF.
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In the present report, we found that a wide variety of
growth factors directly stimulated the activation of the prolif-
eration and survival pathways in lymphatic endothelial cells
from the mouse mesentery and that these signaling cas-
cades can be inhibited by physiologically relevant doses of
AEE788. Some of these cytokines appear to preferentially
activate either Akt or ERK1/2 signaling. For example, the
activity of bFGF was more focused on ERK1/2, whereas
VEGF-A preferentially stimulated Akt signaling. Although
AEE788 has been shown to preferentially inhibit EGFR and
VEGFR-2 kinase activity, higher concentrations of AEE788
have been shown to quench the activity of VEGFR-3 in vitro
[28]. VEGFR-2 heterodimerization with VEGFR-3 can regu-
late tyrosine phosphorylation sites within the cytoplasmic tail
region of VEGFR-3 [51]. Studies also suggest that VEGFR-2
may be necessary for the intracellular signaling initiated by
VEGFR-3 [52]. Although this study did not intend to investi-
gate the interactions between VEGFR-2 and VEGFR-3, the
generation of an immortalized lymphatic endothelial cell line
should facilitate studies of these complex cellular inter-
actions. Previous studies have shown that AEE788 can sig-
nificantly reduce tumor microvascular density by inhibiting
the activation of EGFR and VEGFR [22–24]. Here, we
provide preliminary evidence that AEE788 can also target
receptor tyrosine kinases on tumor-associated lymphatic
vessels and contribute to the therapy of tumors.
Because the tumor cell invasion of lymphatic vessels in
colon cancer is known to be a negative indicator for survival
[13], several investigations have focused their efforts on de-
fining the role of lymphangiogenesis in this disease. Initial
studies reported high expression levels of the lymphangio-
genic growth factors VEGF-C and VEGF-D in human colo-
rectal cancers, but whether the expression of these growth
factors predicts lymph node metastasis is not clear [17–20].
LVD has been associated with lymph node metastasis in
human colon cancer [14–16]; however, there are conflicting
reports as to whether colon tumors possess intratumoral
lymphatic vessels [14–16]. The sensitivity and the specificity
Figure 7. Double-immunofluorescence staining for total and phosphorylated VEGFR-2, VEGFR-3, and EGFR in peritumoral lymphatic vessels. (A) Samples were
stained with anti –LYVE-1 antibody (green) and anti-EGFR, anti –VEGFR-2, or anti –VEGFR-3 (red) antibody, as described in the Materials and Methods section.
The colocalization of LYVE-1 and receptors appears as yellow fluorescence. The expression of EGFR, VEGFR-2, and VEGFR-3 was found in peritumoral
lymphatic vessels of mice treated with control or AEE788. (B) Phosphorylation of EGFR and VEGFR-2/3 in lymphatic endothelial cells was decreased by treatment
with AEE788. Scale bars = 100 m.
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of routinely used lymphatic markers are variable [9]. We
characterized lymphatic vessels using multiple markers, in-
cluding CD31, VEGFR-3, and LYVE-1, and were unable to
detect intratumoral lymphatic vessels. Our finding that HT29
human colon cancer growing orthotopically within the cecum
of nude mice is devoid of lymphatic vessels is in agreement
with more recent studies evaluating human colon cancer
specimens [15,16].
Our findings indicate that lymphangiogenesis plays an
important role in the dissemination of colon cancer into re-
gional lymph nodes. We also demonstrate that, in addition to
tumor cells and tumor-associated vascular endothelial cells,
lymphatic endothelial cells represent an additional target for
the therapy of colon cancer with small molecule tyrosine
kinase inhibitors.
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